Dr. Hu is named a Highly Cited Researcher for 2019 by the Web of Science Group.
Our lab's work on a precision nanoparticle vaccine platform is selected as the highlight technology in the 2019 Future Tech Expo organized by the Ministry of Science and Technology. Congratulations!
Seny Liu received the Excellent Poster Award at the 16th Symposium of the Frontiers of Biomedical Sciences. Congratulations!
Dr. Hu received the 15th Young Scholar Award from the TienTe Lee Biomedical Foundation.
Our work on gelated cell technology for anticancer T cell expansion received the Best Poster Award at the 2019 Gordon Research Conference on cancer nanotechnology. Congratulations!
Seny Liu obtained her Ph.D. with the highest honors (#1 rank) from her graduating class. Congratulations Dr. Liu.
Saborni received the Academia Sinica Travel Grant Award to attend the 2019 Gordon Research Conference on Cancer Nanotechnology. Congratulations!
Dr. Hu is co-appointed as an investigator by the Research Center for Applied Nanomedicine at the National Cheng Kung University.
Dr. Hu received the Excellent Young Investigator Award and Sherry Tsai received the Best Poster Award at the 2019 Annual Meeting of Biomaterials and Controlled Releases Society in Taiwan. Congratulations!
Our lab's international collaboration work on a MERS-CoV nanoparticle vaccine for emerging disease prevention is accepted for publication by Advanced Functional Materials.
Our lab's work on a novel intracellular hydrogelation technology is accepted for publication by Nature Communications.
Che-Ming Jack Hu (胡哲銘）
Associate Research Fellow
Institute of Biomedical Sciences, Academia Sinica
Dr. Jack Hu recevied his Ph.D. in Biomedical Engineering from the University of California, San Diego in 2011 and recevied postdoctoral trainings in the Nanoengineering Department of UCSD. He holds a B.S. degree in Biomedical Engineering with minors in Mechanical Engineering and Electrical Engineering from UC Berkeley.
Nanotechnology in medicine has shown tremendous value in drug delivery and vaccine preparations, where pharmacokinetics and immune activation can be finely tuned via rational nanomaterials engineering. The research focus of the laboratory is to develop novel therapeutic nanomaterials with an emphasis toward clinical translation. We seek to adopt an engineering approach to improve treatments for major diseases including cardiovascular disease, cancer, and infectious disease.